Pfizer may sell off Hospira unit for $2 billion
Pfizer is reportedly considering selling Hospira’s infusion pump business for around $2 billion, having acquired the injectable drugs and infusion device specialist in September.
Bloomberg quoted “people familiar with the matter”, who said talks over the sale were in early stages and the details could change. Pfizer – bought Hospira for $15billion – has so far declined to comment.
Computerised infusion pumps are used to deliver medications directly into patients’ bloodstreams in controlled doses.
Although the deal for Hospira was dwarfed by its $160 billion purchase of Allergan at the end of 2015, Pfizer strengthened considerably in biosimilars and injectables with the earlier purchase. One of Hospira’s star products is a biosimilar version of Janssen’s Remicade (infliximab), already approved in Europe.
This week, Pfizer and Allergan intimated that they were not getting the deserved respect for their combined portfolios, with Pfizer research chief Mikael Dolsten calling Allergan’s pipeline ‘underappreciated’. Allergan currently has promising treatments including depression treatment rapastinel and schizophrenia and bipolar disorder therapy Vraylar in various stages of development.
Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …